natgillin/translations-raw huggingface dataset:
For børn og unge fra 5 til 17 år med kronisk hepatitis C og et legemsoverfladeareal (BSA) større end 0,7 m2, er de anbefalede doser for Pegasys og ribavirin angivet i tabel 4 og i tabel 5.
For children and adolescents aged 5 to 17 years with chronic hepatitis C, and having a Body Surface Area (BSA) greater than 0.7 m2, the recommended doses for Pegasys and ribavirin are provided in Table 4 and Table 5.
For børn og voksne er startdosis 150 mg pr. kvadratmeter kropsoverflade (beregnet ved hjælp af barnets højde og vægt) eller 4 mg/kg én gang dagligt i to uger med Viramune oral suspension, hvorefter dosis bør øges til en vedligeholdelsesdosis (beregnet ved hjælp af patientens kropsoverflade eller vægt).
For children and adolescents, the starting dose is 150 mg per square metre of body surface area (calculated using the child’s height and weight) or 4 mg/kg once a day for two weeks with Viramune oral suspension, after which the dose should be increased to a maintenance dose (calculated using the patient’s body surface area or weight).
For børn op til 12 år, er dosis baseret på kropsstørrelse (overfladeareal), og den sædvanlige dosis er 1,30 g/m2 af kropsareal per dag.
For children up to age 12 years, the dose will be based on the body size (surface area), the usual dose being 1.30 g/m2 of body surface area per day.
For børn over 10 år er den daglige dosis 6 g pr. dag fordelt på 2 doser à 3 g pr. dag.
For children above 10 years of age, the daily dose is 6 g per day given in 2 doses of 3 g per day.
For børn under 12 år beregnes den anbefalede daglige dosis ud fra legemsoverfladen (dvs. patientens højde og vægt), som 1,30 g per m2 fordelt på 4 doser.
For children up to the age of 12 years, the recommended daily dose is calculated according to body surface area (which is calculated from the patient’s height and weight), as 1.30 g per m2 divided into 4 doses.
For børn  11 år kan Nespo i vedligeholdelsesfasen stadig administreres som en enkelt indsprøjtning en gang om ugen eller en gang hver anden uge.
For paediatric patients  11 years of age, in the maintenance phase, Nespo may continue to be administered as a single injection once weekly or once every two weeks.
For børn � 1 år kan Aranesp i vedligeholdelsesfasen stadig administreres som en enkelt indsprøjtning en gang om ugen eller en gang hver anden uge.
For paediatric patients  1 year of age, in the maintenance phase, Aranesp may continue to be administered as a single injection once weekly or once every two weeks.
For børn, der er 6 år og ældre, bør Keppra oral opløsning anvendes ved doser under 250 mg, for doser, som ikke er delelig med 250 mg, når anbefalet dosis ikke kan opnås ved at tage flere tabletter og til p atienter, som ikke er i stand til at synke tabletter.
For children 6 years and above, Keppra oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets
For børn, der er 6 år og ældre, bør Keppra oral opløsning anvendes ved doser under 250 mg, for doser, som ikke er delelig med 250 mg, når anbefalet dosis ikke kan opnås ved at tage flere tabletter og til p atienter, som ikke er i stand til at synke tabletter.
For children 6 years and above, Keppra oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.
For børn, der vejer mere end 5 kg, kan dosen blandes med en spiseskefuld mælk eller frugtjuice (cirka 15 ml).
For children weighing more than 5 kg the dose may be mixed with a tablespoonful of milk or fruit juice (approximately 15 mL).
For børn, der vejer op til 5 kg kan du blande dosen med en teskefuld mælk (cirka 5 ml).
For children weighing up to 5 kg you may mix the dose with one teaspoonful of milk (approximately 5 mL).
For børn, der vejer under 30 kg, og som tager valproat (en behandling af epilepsi), er den maksimalt anbefalede daglige dosis Inovelon 600 mg om dagen.
For children less than 30 kg who are taking valproate (a treatment for epilepsy) the maximum recommended daily dose of Inovelon is 600 mg a day.
For cancerpatienter anbefales jerntilskud (elementært jern 200-300 mg /dag oralt), hvis transferrinmætningen er under 20%.
For cancer patients, iron supplementation (elemental iron 200 to 300 mg/day orally) is recommended if transferrin saturation is below 20%.
For capecitabin dosis-justeringer se capecitabins produktresumé.
For capecitabine dose modifications, see capecitabine summary of product characteristics.
For capecitabin dosis-justeringer, se capecitabins produktresumé.
For capecitabine dose modifications, see capecitabine summary of product characteristics.
For capecitabin dosisjusteringer se capecitabins produktresumé.
For capecitabine dose modifications, see capecitabine summary of product characteristics.
For capecitabin dosisjusteringer, se capecitabins produktresumé.
For capecitabine dose modifications, see capecitabine summary of product characteristics.
For capecitabin dosismodifikationer: se capecitabins produktresumé.
For capecitabine dose modifications, see capecitabine summary of product characteristics.
For CAPS-patienter: nødvendigheden af at instruere patienterne i den korrekte teknik til selvadministration, når patienten er villig til og har mulighed for at gøre dette, samt vejledning til sundhedspersonale i rapportering af administrationsfejl;
For CAPS patients: the need to instruct patients on proper techniques for self-administration when the patient is willing and capable to do so, and guidance for Health Care Professionals on how to report administration errors;
For catch-up-vaccination var vaccineeffektiviteten 33,2 % (95 % CI: 3,0; 53,4) i 7-11 måneders- kohorten og 22,4 % (95 % CI: -8,7; 44,8) i 12-18 måneders-kohorten.
For catch-up vaccination, vaccine effectiveness was 33.2% (95% CI: 3.0; 53.4) in the 7-11 month cohort and 22.4% (95% CI: -8.7; 44.8) in the 12-18 month cohort.
For Cmax er den intraindividuelle variation af inhaleret insulin større end for subkutant administreret hurtigtvirkende humant insulin.
For Cmax, the intrasubject variability of inhaled insulin is greater than that of subcutaneously administered fast- acting human insulin.
For CML og GIST kan din læge foreskrive højere eller lavere dosis afhængigt af, hvordan du reagerer på behandlingen.
For CML and GIST, your doctor may prescribe a higher or lower dose depending on how you respond to the treatment.
For CP-patienter, tillades baseline- respondenter som fastholdt respons efter baseline, i analysen.
For CP patients, the analyses allow baseline responders who maintained response post-baseline to be responders.
For CR1-patienter øgedes den gennemsnitlige varighed af leukæmifri overlevelse fra 291 dage (9,7 måneder) til 450 dage (15 måneder) efter Ceplene/IL-2 i forhold til ingen vedligeholdelsesbehandling (ITT, p=0,01. n=261).
For CR1 patients, the median duration of leukaemia-free survival increased from 291 days (9.7 months) to 450 days (15 months) after Ceplene/IL-2 versus no maintenance treatment (ITT, p=0.01. n=261).
For CRM- baseret konjugeret Hib vaccine konstateredes forøgelse af antistofresponsen på Hib og difteri i spædbarnsgruppen.
For CRM-based Hib conjugate vaccine, enhancement of antibody responses to Hib and diphtheria in the infant series was observed.
For cyklus 4-10 består hver cyklus af 3 ugers behandling efterfulgt af en 6-ugers behandlingsfri periode.
For cycles 4-10, each cycle consists of 3 weeks of treatment, followed by a 6-week treatment- free period.
For CYP2C9 og CYP3A4-substrater er induktionen forbigående, og maksimal effekt opnås efter 3-5 dage efter afslutning af 3-dages EMEND behandling.
For CYP2C9 and CYP3A4 substrates, the induction is transient with a maximum effect reached 3-5 days after end of the EMEND 3-day treatment.
For dabigatran inkluderer det alle blødninger, som forekom i løbet af behandling med dabigatran.
This includes all bleeding events, which occurred during dabigatran etexilate therapy.
For de 40 % af børnene <9 kg, der ikke nåede målet, var AUC jævnt fordelt enten under eller over målgrænserne, dvs.
For the 40% of children < 9 kg outside the target, the AUC was evenly distributed either below or above the targeted limits; i.e.
For de 40% af børnene <9 kg, der ikke nåede målet, var AUC jævnt fordelt enten under eller over målgrænserne, dvs.
For the 40% of children < 9 kg outside the target, the AUC was evenly distributed either below or above the targeted limits; i.e.
For de 77 patienter som fortsatte entecavirbehandling ud over de 52 uger (i gennemsnit 96 uger), havde 40% af patienterne HBV-DNA < 300 kopier/ml ved PCR, og 81% af patienterne havde ALAT- normalisering (≤ 1 gange ULN) ved behandlingens afslutning.
For the 77 patients who continued entecavir treatment beyond 52 weeks (median 96 weeks), 40% of patients had HBV DNA < 300 copies/ml by PCR and 81% had ALT normalisation ( 1 times ULN) at end of dosing.
For de 77 patienter, som fortsatte entecavirbehandling ud over de 52 uger (i gennemsnit 96 uger), havde 40% af patienterne HBV-DNA < 300 kopier/ml ved PCR, og 81% af patienterne havde ALAT- normalisering (≤ 1 gange ULN) ved behandlingens afslutning.
For the 77 patients who continued entecavir treatment beyond 52 weeks (median 96 weeks), 40% of patients had HBV DNA < 300 copies/ml by PCR and 81% had ALT normalisation ( 1 times ULN) at end of dosing.
For de andre kræftformers vedkommende afbrydes behandlingen, hvis sygdommen forværres, eller hvis patienten ikke tåler behandlingen.
For other types of cancer, treatment is stopped if the disease gets worse or the patient cannot tolerate the treatment.
For de antiretrovirale lægemidler, der skal tages samtidig med HCV-behandling, henvises der til de tilsvarende SmPC’er for opmærksomhed på og håndtering af toksiciteter, der er specifikke for det enkelte præparat og potentialet for overlappende toksiciteter med ribavirin.
Please refer to the corresponding SmPC of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ribavirin.
For de antiretrovirale lægemidler, der skal tages samtidig med HCV-behandling, henvises der til disses respektive produktresuméer for kendskab og håndtering af toksiciteter, der er specifikke for det enkelte produkt samt potentialet for overlappende toksiciteter med ribavirin i kombination med peginterferon alfa-2b.
Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ribavirin in combination with peginterferon alfa-2b.
For de antiretrovirale lægemidler, der skal tages samtidig med HCV-behandling, henvises der til disses respektive produktresuméer for kendskab og håndtering af toksiciteter, der er specifikke for det enkelte produkt samt potentialet for overlappende toksiciteter med ribavirin og peginterferon alfa-2b.
Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ribavirin and peginterferon alfa-2b.
For de antiretrovirale lægemidler, der skal tages samtidig med HCV-behandling, henvises der til disses respektive produktresuméer for kendskab og håndtering af toksiciteter, der er specifikke for det enkelte produkt samt potentialet for overlappende toksiciteter med Ribavirin Teva Pharma B.V. i kombination med peginterferon alfa-2b.
Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with Ribavirin Teva Pharma B.V in combination with peginterferon alfa-2b.
For de antiretrovirale lægemidler, der skal tages samtidig med HCV-behandling, henvises der til disses respektive produktresuméer for kendskab til og håndtering af toksiciteter, der er specifikke for det enkelte produkt samt potentialet for overlappende toksiciteter med Ribavirin BioPartners og peginterferon alfa-2b.
Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with Ribavirin BioPartners and peginterferon alfa-2b.
For de behandlingsnaive pædiatriske patienter var middel- baseline-CD4-celletal 344 celler/mm3 (interval 2-800 celler/mm3), og middel-baseline-plasma hiv-1- RNA var 4,67 log10 kopier/ml (interval 3,70-5,00 log10 kopier/ml).
For treatment-naive paediatric patients, the mean baseline CD4 cell count was 344 cells/mm3 (range: 2 to 800 cells/ mm3) and mean baseline plasma HIV-1 RNA was 4.67 log10 copies/ml (range: 3.70 to 5.00 log10 copies/ml).
For de behandlingsnaive pædiatriske patienter var middel- baseline-CD4-celletal 344 celler/mm3 (interval: 2-800 celler/mm3), og middel-baseline-plasma hiv-1- RNA var 4,67 log10 kopier/ml (interval: 3,70-5,00 log10 kopier/ml).
For treatment-naive paediatric patients, the mean baseline CD4 cell count was 344 cells/mm3 (range: 2 to 800 cells/ mm3) and mean baseline plasma HIV-1 RNA was 4.67 log10 copies/ml (range: 3.70 to 5.00 log10 copies/ml).
For de benzodiazepiner som ikke metaboliseres via CYP3A4 (temazepam, nitrazepam, lorazepam) er interaktion med telithromycin usandsynlig.
For those benzodiazepines which are not metabolised by CYP3A4 (temazepam, nitrazepam, lorazepam) an interaction with Ketek is unlikely.
For de bivirkninger, der er markeret med *, er en præcis vurdering af hyppigheden ikke mulig, da disse bivirkninger ikke blev set i kliniske studier med 2762 patienter behandlet med pramipexol.
For the side effects marked with * a precise frequency estimation is not possible, since these side effects were not observed in clinical studies among 2,762 patients treated with pramipexole.
For de børn, hvis mødre har taget medicin som Viread (NRTI'er) i løbet af graviditeten, opvejede fordelen ved beskyttelsen mod virus risikoen ved bivirkningerne.
In children whose mothers took medicines like Viread (NRTIs) during pregnancy, the benefit from the protection against the virus outweighed the risk of side effects.
For de børn, hvis mødre har taget NRTI'er i løbet af graviditeten, opvejede fordelen ved beskyttelsen mod hiv ved bivirkningerne.
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
For de børn, hvis mødre har taget NRTI'er i løbet af graviditeten, opvejede fordelen ved beskyttelsen mod hivrisikoen ved bivirkningerne.
In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIVoutweighed the risk of side effects.
For de deltagere, der udfyldte dagbogen i hvert af disse studier, blev der påvist statistisk signifikante forbedringer ved uge 12 fra udgangsværdien i patientrapporterede tegn og symptomer på kløe, smerte og afskalning sammenlignet med placebo.
For the participants completing the diary in each of these studies, statistically significant improvements at Week 12 from baseline compared to placebo in patient-reported signs and symptoms of itching, pain and scaling were demonstrated.
For de fleste patienter ligger den passende dosis mellem 6 mg og 8 mg dagligt (nås inden for 3 til 4 uger).
For most patients, the right dose is between 6 mg and 8 mg per day (reached within 3 to 4 weeks).
For de fleste patienter ligger den passende dosis mellem 8 mg og 16 mg dagligt (nås inden for 3 til 7 uger).
For most patients, the right dose is between 8 mg and 16 mg per day (reached within 3 to 7 weeks).
For de fleste patienter ligger vedligeholdelsesdosis mellem 200 mg og 400 mg pr. dag.
For most patients the maintenance dose is between 200 mg and 400 mg per day.
For de fleste patienter med hårcelleleukæmi kan ses normalisering af en eller flere hæmatologiske variable inden for en til to måneders IntronA-behandling.
For most patients with Hairy Cell Leukaemia, normalisation of one or more haematological variables occurs within one to two months of IntronA treatment.
For de fleste patienter med type 1-diabetes kan skift til Tresiba ske enhed til enhed ud fra den tidligere basalinsulindosis efterfulgt af individuelle dosisjusteringer.
For most patients with type 1 diabetes, changing the basal insulin to Tresiba can be done unit-to-unit based on the previous basal insulin dose with subsequent individual dosage adjustments.
For de fleste patienter reducerer 2 behandlingsforløb MS-aktiviteten i 2 år.
For most patients 2 treatment courses reduces MS activity for 2 years.
For de fleste racer er anvendelse af ibafloxacin kontraindikeret for hunde yngre end 8 måneder; for de tungeste racer yngre end 18 måneder.
For the majority of breeds the use of ibafloxacin is contra-indicated in dogs less than 8 months of age and in giant breeds less than 18 months.
For de fleste racer er anvendelse af ibafloxacin kontraindikeret for hunde, der er yngre end 8 måneder og for de tungeste racer, der er yngre end 18 måneder.
For the majority of breeds the use of ibafloxacin is contra-indicated in dogs less than 8 months of age, and in giant breeds less than 18 months.
For de fleste racer er anvendelse af ibafloxacin kontraindikeret for hunde, der er yngre end 8 måneder og for de tungeste racer, der er yngre end 18 måneder.
For the majority of breeds, the use of ibafloxacin is contra-indicated in dogs less than 8 months of age, and in giant breeds less than 18 months.
For de forsøgspersoner, som gennemførte Forsøg 1-forlængelsesstudiet (ospemifen, n=41; placebo, n= 18), og de forsøgspersoner, som deltog i det langvarige sikkerhedsstudie af 52 ugers varighed (Forsøg 3: ospemifen, n=276; placebo, n=46), blev endometriel sikkerhed vurderet med endometriebiopsi ved baseline og efter12 måneder.
For subjects completing the Trial 1 extension study (ospemifene, n=41; placebo, n= 18) and for subjects in the long-term 52-week safety study (Trial 3: ospemifene, n=276; placebo, n=46), endometrial safety was assessed by endometrial biopsy at baseline and at 12 months.
For de følgende transportere blev klinisk relevant hæmning ekskluderet på basis af en afskæring på IC50 > 50  Cmax, ubundet.
For the following transporters, clinically relevant inhibition was excluded based on a cutoff of IC50> 50  Cmax,unbound.
For de patienter (n = 102) med recidiv efter 180 dage, var medianoverlevelse 9,9 mdr. i gruppen, der fik topotecan + cisplatin (95 % C.I.: 7; 12,6) versus 6,3 mdr. (95 % C.I.: 4,9; 9,5) i gruppen, der fik cisplatin alene med et risikoforhold på 0,75 (0,49; 1,16).
9.9 months (95 % C.I.: 7, 12.6) versus 6.3 months (95 % C.I.: 4.9, 9.5) for the cisplatin arm with an hazard ratio of 0.75 (0.49, 1.16).
For de patienter (n = 102) med recidiv efter 180 dage, var medianoverlevelse i gruppen, der fik topotecan + cisplatin 9,9 mdr. (95 % C.I.: 7; 12,6) versus 6,3 mdr.
In those (n = 102) with recurrence after 180 days, the median survival in the topotecan plus cisplatin arm was
For de patienter, der fik asfotase alfa: 9/13 patienter viste vedvarende, tydelig indhentning af vækstøgningen som vist ved skiftet med tiden til en højere percentil på CDC-vækstkurver.
For those patients who received asfotase alfa: 9/13 patients displayed persistent apparent catch-up height-gain as shown by movement over time to a higher percentile on CDC growth charts.
For de patienter, der udvikler knoglenekrose i kæben, mens de er i behandling med bisphosphonater, kan en tandkirurgi forværre tilstanden.
For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition.
For de patienter, hvor behandlingen med Eviplera svigtede og som udviklede resistens over for Eviplera, blev der generelt set krydsresistens over for andre godkendte NNRTI’er (etravirin, efavirenz, nevirapin).
For those patients failing therapy with Eviplera and who developed resistance to Eviplera cross resistance to other approved NNRTIs (etravirine, efavirenz, nevirapine) was generally seen.
For de patienter, som fik > 10,6 mg/kg ribavirin (800 mg dosis til en typisk patient på 75 kg), uafhængigt af genotype eller virusmængde, var responsrater signifikant højere end for de patienter, der fik ≤ 10,6 mg/kg ribavirin (Tabel 6), mens responsrater for patienter, der fik > 13,2 mg/kg ribavirin, var endnu højere.
In those patients that received > 10.6 mg/kg ribavirin (800 mg dose in typical 75 kg patient), regardless of genotype or viral load, response rates were significantly higher than in those patients that received ≤ 10.6 mg/kg ribavirin (Table 6), while response rates in patients that received > 13.2 mg/kg ribavirin were even higher.
For de patienter, som fik > 10,6 mg/kg ribavirin (800 mg dosis til en typisk patient på 75 kg), uafhængigt af genotype eller virusmængde, var responsrater signifikant højere end for de patienter, der fik ≤10,6 mg/kg ribavirin (Tabel 6), mens responsrater for patienter, der fik > 13,2 mg/kg ribavirin, var endnu højere.
In those patients that received > 10.6 mg/kg ribavirin (800 mg dose in typical 75 kg patient), regardless of genotype or viral load, response rates were significantly higher than in those patients that received ≤ 10.6 mg/kg ribavirin (Table 6), while response rates in patients that received > 13.2 mg/kg ribavirin were even higher.
For de patienter, som fik > 10,6 mg/kg ribavirin (800 mg dosis til en typisk patient på 75 kg), uafhængigt af genotype eller virusmængde, var responsrater signifikant højere end for de patienter, der fik ≤10,6mg/kg ribavirin (Tabel 6), mens responsrater for patienter, der fik > 13,2 mg/kg ribavirin, var endnu højere.
In those patients that received > 10.6 mg/kg ribavirin (800 mg dose in typical 75 kg patient), regardless of genotype or viral load, response rates were significantly higher than in those patients that received ≤ 10.6 mg/kg ribavirin (Table 6), while response rates in patients that received > 13.2 mg/kg ribavirin were even higher.
For de patienter, som ikke tolererer tadalafil 5 mg for behandling af benign prostatahyperplasi, skal anden behandling overvejes, da virkningen af tadalafil 2,5 mg til behandling af benign prostatahyperplasi ikke er vist.
5 mg for the treatment of benign prostatic hyperplasia should consider an alternative therapy as the efficacy of tadalafil 2.5 mg for the treatment of benign prostatic hyperplasia has not been demonstrated.
For de personer, hvor dosis blev reduceret til 30 mg (hovedsageligt lav legemsvægt eller nyrefunktion) havde 15 (2,1 %) personer, der fik edoxaban og 22 (3,1 %) af de personer, der fik warfarin, recidiverende VTE [HR (95 % CI): 0,69 (0,36; 1,34)].
For the subjects who were dose reduced to 30 mg (predominantly low body weight or renal function) 15 (2.1%) edoxaban and 22 (3.1%) of warfarin subjects had a recurrent VTE [HR (95% CI): 0.69 (0.36, 1.34)].
For de primære endepunkter apopleksi og systemisk emboli fandt man for alle delpopulationer (såsom alder, vægt, køn, nyrefunktion, etnicitet, mv.) samme risikoreduktion sammenlignet med warfarin.
For the primary endpoint, stroke and SEE, no subgroups (i.e., age, weight, gender, renal function, ethnicity, etc.) were identified with a different risk ratio compared to warfarin.
For de primære endepunkter, apopleksi og systemisk emboli fandt man for alle delpopulationer (såsom alder, vægt, køn, nyrefunktion, etnicitet, mv.) samme risikoreduktion sammenlignet med warfarin.
For the primary endpoint, stroke and SEE, no subgroups (i.e., age, weight, gender, renal function, ethnicity, etc.) were identified with a different risk ratio compared to warfarin.